Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VPHM - Viropharma Inc -- Ignore unavailable to you. Want to Upgrade?

To: CoffeePot who wrote (80)	7/14/1999 2:32:00 PM
From: Saulamanca	Read Replies (1) \| Respond to of 2557

Everybody and their brother must see this as a slam dunk short. Makes you wonder ? This from briefing.com: "ViroPharma Inc. (VPHM) 18 1/16 +5 1/4: The search for curing the common cold continues and investors are betting that this developer and discoverer of antiviral pharmaceuticals may be on the right path. For the second consecutive day, shares of ViroPharma are rising (+41%) and are one of the most active shares being traded on the Nasdaq after the company announced yesterday that it had achieved successful Phase 2 results with pleconaril to treat patients with viral respiratory infections. Yesterday's announcement allowed the stock to gain 39% but it appears that not everyone found out about ViroPharma's success at the same time as the stock has made further advances this morning. Given that the shares closed at $9 1/4 on Monday, the stock is up more than 95% in less than two days. While finding a cure for the common cold has been something that science has been searching for eons, there is no guarantee that pleconaril is the answer since it failed in the treatment of viral meningitis when trials did not support the drug's initial claim. However, according to ViroPharma, in their latest trials patients that were treated with pleconaril recovered faster by about three days from their severe viral infection than patients that were given a placebo. The successful Phase 2 results has prompted ViroPharma to proceed with Phase 3 studies in hopes that pleconaril will provide relief in the treatment of severe forms of the common cold. These Phase 3 trials will take time and the results may not be know for at least another year. Hence, investors that lack the patience and expect a remedy to be on the market anytime soon are jumping the gun. Even if ViroPharma has uncovered the Holy Grail, a long road still lies ahead which includes obtaining FDA approval."